METHODS	In this prospective , randomized , open-label , and single center study , a total of 300 patients with NSTE-ACS were randomized to receive either fondaparinux ( group F , n = 150 , 2.5 mg/d ) or nadroparin ( group N , n = 150 , 0.1 ml/10 kg q12 h ) for a mean of 4 days .\